ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.Future oncology (London, England) · 2014Pooled it
- Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients.Breast cancer research and treatment · 2025Article
- Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach.Pharmacoepidemiology and drug safety · 2025Article
- Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases.Scientific reports · 2018Article
- Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.Acta oncologica (Stockholm, Sweden) · 2018Article
- Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.Breast cancer research and treatment · 2016Article
- A review of significant pharmacokinetic drug interactions with antidepressants and their management.The mental health clinician · 2016Review
- Breast cancer recurrence in relation to antidepressant use.Cancer causes & control : CCC · 2016Article
- Risk of emergent bradycardia associated with initiation of immediate- or slow-release metoprolol.Pharmacotherapy · 2013Article
- Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.American journal of clinical oncology · 2013Article
- Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.Molecular oncology · 2012Review
- Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Expert review of clinical pharmacology · 2011Review
- CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Seminars in oncology · 2011Review
- CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Journal of the National Cancer Institute · 2011Article
- Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma.Biochemical pharmacology · 2010Review
- The Impact of CYP2D6 Genotyping on Tamoxifen Treatment.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.Acta oncologica (Stockholm, Sweden) · 2010Article
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.BMJ (Clinical research ed.) · 2010Article
- CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.Current oncology reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null (OR, 1.0; 95% confidence interval, 0.8-1.3); recurrence ORs for individual drugs ranged from 0.3 to 3.4. The individual ORs followed the pattern expected under a null-centered Gaussian distribution. Null associations were apparent for all drugs after empirical Bayes adjustment for multiple comparisons. Together, these results provide evidence for a null association between drug-compromised CYP2D6 activity and breast cancer recurrence among tamoxifen-treated women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.